-
Vivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) GalleryVivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
-
Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders Gallery
Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders
-
Vivo Capital’s venture portfolio company AADI announces a merger agreement with Aerpio Pharmaceuticals with a concurrent $155M in PIPE financing by Aerpio Pharmaceuticals Gallery
Vivo Capital’s venture portfolio company AADI announces a merger agreement with Aerpio Pharmaceuticals with a concurrent $155M in PIPE financing by Aerpio Pharmaceuticals
-
Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)! Gallery
Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)!
-
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China Gallery
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
-
Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant Expanded Access Program For Pitolisant Is Open And Patients Are Being Enrolled Gallery
Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant Expanded Access Program For Pitolisant Is Open And Patients Are Being Enrolled